Duality Advisers, LP Sage Therapeutics, Inc. Transaction History

Duality Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$27.52 - $37.99 $284,529 - $392,778	-10,339 Reduced 34.84%	19,334 $624,000
Q1 2022 May 09, 2022	BUY	$30.71 - $45.71 $911,257 - $1.36 Million	29,673 New	29,673 $982,000
Q4 2021 Feb 02, 2022	SELL	$37.06 - $47.11 $394,355 - $501,297	-10,641 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$40.26 - $57.37 $428,406 - $610,474	10,641 New	10,641 $472,000
Q4 2020 Feb 09, 2021	SELL	$58.41 - $89.06 $1.26 Million - $1.92 Million	-21,590 Closed	0 $0

Q3 2020 Nov 12, 2020	BUY	$41.13 - $62.45 $887,996 - $1.35 Million	21,590 New	21,590 $1.32 Million

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.